Biocon Biologics Ltd. (BBL), a leading global biosimilars company, announced that its Malaysian subsidiary, Biocon Sdn. Bhd., has surpassed the milestone of supplying over 100 million cartridges of recombinant human insulin (rh-insulin) to Malaysia’s Ministry of Health (MoH). This accomplishment highlights the company’s ongoing commitment to enhancing diabetes care and ensuring affordable insulin access throughout the country.
Since entering the Malaysian market in 2016, Biocon Biologics has played a key role in transforming diabetes management. The company has delivered over 100 million rh-insulin cartridges, serving more than 345,000 patients. Its public-private partnership with the Malaysian government showcases a successful model for fostering a resilient biotech ecosystem—driving innovation, developing local talent, improving patient outcomes, and advancing insulin self-sufficiency in the country.
“Providing over 100 million cartridges of rh-insulin to support 345,000 diabetes patients in Malaysia reflects our strong commitment to equitable diabetes care,” said Susheel Umesh, Chief Commercial Officer, Biocon Biologics. “Each cartridge produced at our cutting-edge Johor facility is a vital lifeline. Our partnership with the Ministry of Health and Duopharma demonstrates how local manufacturing and global expertise can combine to deliver scalable and sustainable healthcare solutions.”
Leonard Ariff Abdul Shatar, Group Managing Director of Duopharma Biotech Berhad, added: “This milestone highlights the strength of our enduring partnership with Biocon Biologics. Together, we’re dedicated to advancing diabetes care by ensuring a steady supply of high-quality, affordable insulin, supporting the Ministry of Health’s goal to build a resilient national healthcare system.”
Globally, Biocon Biologics ranks among the top three suppliers of rh-Insulin and Insulin Glargine. In partnership with Duopharma Marketing Sdn. Bhd., a subsidiary of Duopharma Biotech Berhad, the company has supported Malaysia’s diabetes care efforts since 2016.
Biocon Biologics has invested USD 600 million in its Johor facility, establishing it as a Center of Excellence (CoE) for insulins. The facility offers end-to-end manufacturing capabilities for a wide range of insulins—regular, basal, and rapid—in various forms, including cartridges and delivery devices. Recognizing this, the Malaysia Book of Records has named Biocon Sdn. Bhd. as the first and largest integrated insulin manufacturer in the country.
With a global vision to serve one in every five insulin-dependent patients, Biocon Biologics has cumulatively delivered 9.2 billion doses of rh-Insulin and Insulin Glargine worldwide.